Ikena Oncology Stock Beta
| IKNA Stock | USD 1.73 0.03 1.76% |
Ikena Oncology fundamentals help investors to digest information that contributes to Ikena Oncology's financial success or failures. It also enables traders to predict the movement of Ikena Stock. The fundamental analysis module provides a way to measure Ikena Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ikena Oncology stock.
Ikena | Beta |
Ikena Oncology Company Beta Analysis
Ikena Oncology's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Ikena Oncology Beta | 0.49 |
Most of Ikena Oncology's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ikena Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Ikena Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Ikena Oncology is extremely important. It helps to project a fair market value of Ikena Stock properly, considering its historical fundamentals such as Beta. Since Ikena Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ikena Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ikena Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Ikena Oncology has a Beta of 0.485. This is 43.6% lower than that of the Biotechnology sector and 65.11% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Ikena Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ikena Oncology's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ikena Oncology could also be used in its relative valuation, which is a method of valuing Ikena Oncology by comparing valuation metrics of similar companies.Ikena Oncology is rated below average in beta category among its peers.
Ikena Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Ikena Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ikena Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ikena Oncology's value.| Shares | Sofinnova Ventures | 2024-06-30 | 382.6 K | Blackrock Inc | 2024-06-30 | 354.8 K | Millennium Management Llc | 2024-06-30 | 354.7 K | Goldman Sachs Group Inc | 2024-06-30 | 273.8 K | Geode Capital Management, Llc | 2024-06-30 | 256.7 K | Citadel Advisors Llc | 2024-06-30 | 244.7 K | Two Sigma Investments Llc | 2024-06-30 | 236.9 K | Barclays Plc | 2024-06-30 | 196 K | Two Sigma Advisers, Llc | 2024-06-30 | 173.2 K | Bvf Inc | 2024-09-30 | 4.8 M | Blue Owl Capital Holdings Lp | 2024-06-30 | 4.1 M |
As returns on the market increase, Ikena Oncology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ikena Oncology is expected to be smaller as well.
Ikena Fundamentals
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (97.55) % | ||||
| Current Valuation | (46.15 M) | ||||
| Shares Outstanding | 48.26 M | ||||
| Shares Owned By Insiders | 10.49 % | ||||
| Shares Owned By Institutions | 63.58 % | ||||
| Number Of Shares Shorted | 129.88 K | ||||
| Price To Earning | 3.89 X | ||||
| Price To Book | 0.62 X | ||||
| Price To Sales | 126.69 X | ||||
| Revenue | 9.16 M | ||||
| Gross Profit | (48.7 M) | ||||
| EBITDA | (74.4 M) | ||||
| Net Income | (68.17 M) | ||||
| Cash And Equivalents | 192.81 M | ||||
| Cash Per Share | 5.32 X | ||||
| Total Debt | 10.74 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 6.98 X | ||||
| Book Value Per Share | 2.78 X | ||||
| Cash Flow From Operations | (79.74 M) | ||||
| Short Ratio | 3.02 X | ||||
| Earnings Per Share | (1.23) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 14 | ||||
| Beta | 0.49 | ||||
| Market Capitalization | 83.49 M | ||||
| Total Asset | 192.09 M | ||||
| Retained Earnings | (282.38 M) | ||||
| Working Capital | 164.46 M | ||||
| Net Asset | 192.09 M |
About Ikena Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ikena Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ikena Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ikena Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ikena Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ikena Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ikena Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ikena Oncology Stock:Check out Ikena Oncology Piotroski F Score and Ikena Oncology Altman Z Score analysis. For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Revenue Per Share 0.014 | Quarterly Revenue Growth (0.88) | Return On Assets (0.22) | Return On Equity (0.37) |
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.